End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain.
Humans
Influenza Vaccines
/ immunology
Influenza, Human
/ prevention & control
Middle Aged
Adolescent
Adult
Primary Health Care
/ statistics & numerical data
United Kingdom
/ epidemiology
Aged
Young Adult
Child
Female
Male
Child, Preschool
Influenza A Virus, H3N2 Subtype
/ immunology
Vaccine Efficacy
Influenza B virus
/ immunology
Influenza A Virus, H1N1 Subtype
/ immunology
Seasons
Vaccination
/ statistics & numerical data
effectiveness
influenza
vaccine
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
26
03
2024
received:
15
03
2024
accepted:
29
03
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
ppublish
Résumé
The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2-13 (and 14-15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom. End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders. Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: -6% to 54%). VE for those aged 18-64, who largely received cell-based vaccines, was 47% (95% CI: 37%-56%). Overall VE for 2-17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%-76%). The paper provides evidence of moderate influenza VE in 2022/23.
Sections du résumé
BACKGROUND
BACKGROUND
The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2-13 (and 14-15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.
METHODS
METHODS
End-of-season adjusted vaccine effectiveness (VE) estimates against sentinel primary-care attendance for influenza-like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.
METHODS
METHODS
Results In the mainland United Kingdom, end-of-season VE against all laboratory-confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: -6% to 54%). VE for those aged 18-64, who largely received cell-based vaccines, was 47% (95% CI: 37%-56%). Overall VE for 2-17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%-76%).
CONCLUSION
CONCLUSIONS
The paper provides evidence of moderate influenza VE in 2022/23.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13295Subventions
Organisme : UK Health Security Agency
Organisme : Public Health Scotland
Organisme : Public Health Wales
Informations de copyright
© 2024 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
UK Health Security Agency, “Surveillance of Influenza and Other Seasonal Respiratory Viruses in Winter 2021 to 2022,” UK Health Security Agency, 30/09/2022, (2022), https://www.gov.uk/government/statistics/annual‐flu‐reports/surveillance‐of‐influenza‐and‐other‐seasonal‐respiratory‐viruses‐in‐winter‐2021‐to‐2022.
Public Health England, “Surveillance of Influenza and Other Seasonal Respiratory Viruses in the UK: Winter 2020 to 2021,” (2021), https://webarchive.nationalarchives.gov.uk/ukgwa/20220401215804mp_/https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/995284/Surveillance_of_influenza_and_other_seasonal_respiratory_viruses_in_the_UK_2020_to_2021‐1.pdf.
UK Health Security Agency, “Surveillance of Influenza and Other Seasonal Respiratory Viruses in the UK, Winter 2022 to 2023,” (2023), https://www.gov.uk/government/statistics/annual‐flu‐reports/surveillance‐of‐influenza‐and‐other‐seasonal‐respiratory‐viruses‐in‐the‐uk‐winter‐2022‐to‐2023.
R. Pebody, H. Whitaker, H. Zhao, et al., “Protection Provided by Influenza Vaccine Against Influenza‐Related Hospitalisation in >/=65 Year Olds: Early Experience of Introduction of a Newly Licensed Adjuvanted Vaccine in England in 2018/19,” Vaccine 38, no. 2 (2020): 173–179.
Department of Health and Social Care, “National Flu Immunisation Programme 2022 to 2023 Letter,” (2022), https://webarchive.nationalarchives.gov.uk/ukgwa/20230515154700/https://www.gov.uk/government/publications/national‐flu‐immunisation‐programme‐plan/national‐flu‐immunisation‐programme‐2022‐to‐2023‐letter.
F. Atherton, “The National Influenza Immunisation Programme 2022–23,” (2022) In: Government W, editor.
Scottish Government, “Winter Vaccination Programme 2022 to 2023: COVID‐19 and Seasonal Flu Deployment Plan,” (2022).
Department of Health and Social Care, “Statement of Amendments to Annual Flu Letter – 21 July 2022,” (2022), https://webarchive.nationalarchives.gov.uk/ukgwa/20230515154735/https:/www.gov.uk/government/publications/national‐flu‐immunisation‐programme‐plan/statement‐of‐amendments‐to‐annual‐flu‐letter‐21‐july‐2022.
B. Hakin, P. Cosford, F. Harvey, and Department of Health, “The Flu Immunisation Programme 2013/14 – Extension to Children,” (2013).
J. C. P. Van‐Tam, and S. Powis, “Annual National Flu Programme Letter 2019 to 2020,” In: Department of Health and Social Care PHE, NHS England, editor. (2019).
E. A. S. M. Belongia, J. P. King, M. E. Sundaram, N. S. Kelley, M. T. Osterholm, and H. Q. McLean, “Variable Influenza Vaccine Effectiveness by Subtype: A Systematic Review and Meta‐Analysis of Test‐Negative Design Studies,” The Lancet Infectious Diseases 16, no. 8 (2016): 942–951.
E. A. Belongia and H. Q. McLean, “Influenza Vaccine Effectiveness: Defining the H3N2 Problem,” Clinical Infectious Diseases 69, no. 10 (2019): 1817–1823.
D. M. Fleming, N. J. Andrews, J. S. Ellis, et al., “Estimating Influenza Vaccine Effectiveness Using Routinely Collected Laboratory Data,” Journal of Epidemiology and Community Health 64, no. 12 (2010): 1062–1067.
“Briefing: Primary Care Providers and the Coronavirus (COVID‐19) [Press Release],” 18/02/2020, (2020), https://www.england.nhs.uk/coronavirus/documents/briefing‐primary‐care‐providers‐and‐the‐coronavirus‐covid‐19/.
J. L. Bernal, M. A. Sinnathamby, S. Elgohari, et al., “The Impact of Social and Physical Distancing Measures on COVID‐19 Activity in England: Findings From a Multi‐Tiered Surveillance System,” Eurosurveillance 26, no. 11 (2021): 2001062.
M. Leston, W. H. Elson, C. Watson, et al., “Representativeness, Vaccination Uptake, and COVID‐19 Clinical Outcomes 2020‐2021 in the UK Oxford‐Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary,” JMIR Public Health and Surveillance 8, no. 12 (2022): e39141.
M. K. Doll, S. M. Pettigrew, J. Ma, and A. Verma, “Effects of Confounding Bias in Coronavirus Disease 2019 (COVID‐19) and Influenza Vaccine Effectiveness Test‐Negative Designs due to Correlated Influenza and COVID‐19 Vaccination Behaviors,” Clinical Infectious Diseases 75, no. 1 (2022): e564–e571.
S. Elbe and G. Buckland‐Merrett, “Data, Disease and Diplomacy: GISAID's Innovative Contribution to Global Health,” Global Challenges 1, no. 1 (2017): 33–46.
S. G. T. T. E. Sullivan and B. J. Cowling, “Theoretical Basis of the Test‐Negative Study Design for Assessment of Influenza Vaccine Effectiveness,” American Journal of Epidemiology 184, no. 5 (2016): 345–353.
E. Kissling, M. Maurel, H.‐D. Emborg, et al., “Interim 2022/23 Influenza Vaccine Effectiveness: Six European Studies, October 2022 to January 2023,” Eurosurveillance 28, no. 21 (2023): 2300116.
H. Q. P. J. McLean, K. E. Hanson, and J. K. Meece, et al. “Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin,” October 2022–February 2023, (2023).
S. L. N. Olson, and M. Tenforde, “Interim Influenza Vaccine Effectiveness Against Inpatient, Emergency Department, and Outpatient Illness in the 2022–23 season,” National Center for Immunization & Respiratory Diseases, CDC, (2023).
D. M. Skowronski, E. S. Chuang, S. Sabaiduc, et al., “Vaccine Effectiveness Estimates From an Early‐Season Influenza a(H3N2) Epidemic, Including Unique Genetic Diversity with Reassortment, Canada, 2022/23,” Eurosurveillance 28, no. 5 (2023): 2300043.
K. Russell, J. R. Chung, A. S. Monto, et al., “Influenza Vaccine Effectiveness in Older Adults Compared With Younger Adults over Five Seasons,” Vaccine 36, no. 10 (2018): 1272–1278.
E. Kissling, F. Pozo, I. Martínez‐Baz, et al., “Influenza Vaccine Effectiveness Against Influenza a Subtypes in Europe: Results From the 2021‐2022 I‐MOVE Primary Care Multicentre Study,” Influenza and Other Respiratory Viruses 17, no. 1 (2023): e13069.
Influenza Virus Characterization: Summary Report, Europe, February 2023 (Copenhagen and Stockholm: World Health Organization and the European Centre for Disease Prevention and Control, 2023).
A. S. Monto, M. Zambon, and J. P. Weir, “The End of B/Yamagata Influenza Transmission—Transitioning from Quadrivalent Vaccines,” The New England Journal of Medicine 390, no. 14 (2024): 1256–1258.
E. Jones‐Gray, E. J. Robinson, A. J. Kucharski, A. Fox, and S. G. Sullivan, “Does Repeated Influenza Vaccination Attenuate Effectiveness? A Systematic Review and Meta‐Analysis,” The Lancet Respiratory Medicine 11, no. 1 (2023): 27–44.